leisure time -WSS

leisure time

author：entertainment 2025-10-01 00:47:18 - browse：29721

Adobe

LONDON — Merck said Wednesday it is buying ophthalmology-focused startup EyeBio in a deal worth up to $3 billion, as the pharma company looks to diversify its pipeline.

Under the deal, Merck, through a subsidiary, will pay $1.3 billion in cash upfront, with another $1.7 billion potentially included if certain regulatory and commercial milestones are met. The Wall Street Journal first reported the news Tuesday night.

EyeBio has been developing a drug called restoret for a number of retinal diseases, including age-related macular degeneration and diabetic macular edema. It presented data in February from a Phase 1/2 trial of restoret in both conditions. Merck said it plans to move restoret into a pivotal trial for diabetic macular edema later this year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： 2 US Navy sailors arrested for allegedly spying for China

focus

WSS

Setback for rare diseases as Taysha Gene Therapies pulls back

The Karikó problem: Lessons for funding basic research

European officials brace for rough respiratory virus season

RSV injection headlines need to be accurate for good uptake

What we owe ALS patients — and why one company fell short

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

knowledge

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

focus

Activists slam private health insurers over coverage restrictions

6 solutions to address cancer drug shortages and others

Sports medicine is finally prioritizing gender equality

Trump drops motion seeking removal of DA probing efforts to overturn 2020 election in Georgia

Activists slam private health insurers over coverage restrictions

2023 Nobel Prize in Medicine goes to Karikó and Weissman

Moonlake's readout produced a cash windfall. Risks remain

OTC birth control: A brief history of over the counter pill design

Psychedelics group wrestles with new pharma identity

CDC: Uninsured rate hit 'record low' right as states cut Medicaid

hotspot

RSV injection headlines need to be accurate for good uptake

Nearly two

What the cancer research community can learn from the Covid response

Lawsuit highlights wrinkle for disputes over surprise medical bills

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

Who is Magistrate Judge Moxila Upadhyaya in Trump's Jan. 6 case?

focus

focus

focus

entertainment